Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)

Raw xml | Download


<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="267226"/>
  <meta>
    <versionId value="14"/>
    <lastUpdated value="2026-09-02T17:15:21.850Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: EvidenceVariable 267226</b></p><a name="267226"> </a><a name="hc267226"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 14; Last updated: 2026-09-02 17:15:21+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="https://fevir.net/resources/EvidenceVariable/267226">https://fevir.net/resources/EvidenceVariable/267226</a></p><p><b>identifier</b>: FEvIR Object Identifier/267226, FEvIR Linking Identifier/NCT03421379-primaryOutcome-0</p><p><b>name</b>: Percentage_of_Participants_Achieving_Treatment_Success_During_Controlled_Insulin_Induced_Hypoglycemia_NCT03421379</p><p><b>title</b>: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)</p><p><b>citeAs</b>: </p><div><p>Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267226. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267226. Computable resource at: https://fevir.net/resources/EvidenceVariable/267226#json.</p>
</div><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration.</p>
</div><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>
</div><h3>Definitions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration.</span></td></tr></table><p><b>handling</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/179423 evidence-variable-handling-not-specified}">Evidence variable handling not specified</span></p><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>Pre-dose up to 30 minutes post each glucagon administration</td></tr></table></div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <url value="https://fevir.net/resources/EvidenceVariable/267226"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="267226"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="NCT03421379-primaryOutcome-0"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="Percentage_of_Participants_Achieving_Treatment_Success_During_Controlled_Insulin_Induced_Hypoglycemia_NCT03421379"/>
  <title
         value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)"/>
  <citeAs
          value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267226. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267226. Computable resource at: https://fevir.net/resources/EvidenceVariable/267226#json."/>
  <status value="active"/>
  <author>
    <name
          value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
  </author>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration."/>
  <copyright
             value="Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse)."/>
  <definition>
    <concept>
      <text
            value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration."/>
    </concept>
  </definition>
  <handling>
    <coding>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-variable-handling-not-specified"/>
      <display value="Evidence variable handling not specified"/>
    </coding>
  </handling>
  <timing>
    <text
          value="Pre-dose up to 30 minutes post each glucagon administration"/>
  </timing>
</EvidenceVariable>